



## Repair Therapeutics to Participate in Two Upcoming Investor Conferences

September 7, 2022

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Sep. 7, 2022-- Repair Therapeutics Inc. ("Repair" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate at two investor conferences in September. Details for the fireside chats are as follows:

### **Morgan Stanley 20th Annual Global Healthcare Conference**

Date: Wednesday, September 14, 2022

Time: 2:55 p.m. Eastern Time

Location: New York, NY

### **Guggenheim Nantucket Therapeutics Conference**

Date: Wednesday, September 28, 2022

Time: 8:00 a.m. Eastern Time

Location: Nantucket, MA

A live webcast of the fireside chats can be accessed in the Investor section of the Company's website at <https://ir.reparerx.com/news-and-events/events>. A replay of the webcasts will be archived on the Company's website for 90 days.

### **About Repair Therapeutics, Inc.**

Repair Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's pipeline includes camonsertib (also known as RP-3500), a potential leading ATR inhibitor currently in Phase 1/2 clinical development partnered with Roche; RP-6306, a PKMYT1 inhibitor currently in Phase 1 clinical development; RP-2119, a Polθ inhibitor program in ongoing IND-enabling studies; as well as several additional, undisclosed preclinical programs. For more information, please visit [reparerx.com](http://reparerx.com).

SNIPRx® is a registered trademark of Repair Therapeutics Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220907005031/en/): <https://www.businesswire.com/news/home/20220907005031/en/>

### **Repair Contact:**

Robin Garner

Executive Director and Head of Investor Relations

Repair Therapeutics Inc.

[info@reparerx.com](mailto:info@reparerx.com)

### **Investors:**

Matthew DeYoung

Argot Partners

[repare@argotpartners.com](mailto:repare@argotpartners.com)

### **Media:**

David Rosen

Argot Partners

[david.rosen@argotpartners.com](mailto:david.rosen@argotpartners.com)

212-600-1902

Source: Repair Therapeutics Inc.